Kinfo
Cartesian Therapeutics, Inc. logo

Cartesian Therapeutics, Inc.

RNACNASDAQHealthcare·US · USD
$6.35
-0.01 (-0.08%)
Prices as of November 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap193.69M USD
Enterprise value131.06M USD
Trailing P/E1.98
Forward P/E-5.00
PEG ratio-0.25
Price / sales188.97
Price / book-1.49
Profitability
Gross margin0.00%
Operating margin-10009.17%
Profit margin0.00%
Return on assets-19.23%
Return on equity103.22%
Income (TTM)
Revenue1.02M USD
Gross profit-69.18M USD
EBITDA-99.81M USD
Net income-127.46M USD
Diluted EPS-$4.78
Rev. growth (YoY)-100.00%
Balance sheet
Total cash122.97M USD
Total debt60.34M USD
Debt / equity-0.48
Current ratio8.38
Book value / share-$4.28
Cash flow (TTM)
Operating cash flow-88.66M USD
Levered free cash flow-58.12M USD
Shares & price
Shares outstanding30.04M
Float11.73M
Held by institutions29.59%
Beta0.76
50-day MA$7.20
200-day MA$7.62
52-week high$11.00
52-week low$5.60
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-05-1.01-0.85+15.84%2026-07-300.200.29+45.00%2026-07-160.751.11+48.00%2026-05-080.110.13+18.18%
About Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s current pipeline centers on autologous CAR-T programs designed to modulate immune activity and address serious conditions such as generalized myasthenia gravis, systemic lupus erythematosus, and certain forms of myositis. Its lead candidate, Descartes-08, is being advanced across multiple autoimmune indications, while additional programs such as Descartes-15 and Descartes-33 expand the company’s research beyond its lead asset. Cartesian Therapeutics emphasizes engineered cell therapy and proprietary manufacturing capabilities to create targeted treatments that fit within the broader fields of immunology, cell therapy, and precision medicine. Headquartered in Frederick, Maryland, Cartesian Therapeutics plays a specialized role in the biotechnology market by focusing on advanced therapies for difficult-to-treat immune-mediated diseases.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Carsten Brunn Ph.D.
Employees
75
Headquarters
Frederick, MD, United States

Frequently asked questions about Cartesian Therapeutics, Inc.